Lipegfilgrastim (XM22), a long acting granulocyte colony-stimulating factor (G-CSF), was added to Teva’s portfolio through the acquisition of ratiopharm.

CG-10639 (formerly Neugranin) Phase II/III data demonstrated non-inferiority to pegfilgrastimDosing study of XM22 supported future Phase III trial of 6mg dose versus pegfilgrastimBoth compounds ...

CONTACT: Investor Relations: Teva Pharmaceutical Industries Ltd. Elana Holzman, 972 (3) 926-7554 or Teva North America Kevin Mannix, 215-591-8912 or ...